A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Methods

• Publication date

  2012-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ymeth.2012.03.018PMID 22465281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers.

  2012cited by this paper
• Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease

  2011cited by this paper
• Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

  2011cited by this paper
• Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10

  2009cited by this paper
• Cerebrospinal Fluid Biomarkers for Alzheimer's Disease

  2009cited by this paper
• Cerebrospinal fluid biomarkers in the evaluation of Alzheimer disease.

  2008cited by this paper
• Integrated analysis of the cerebrospinal fluid peptidome and proteome.

  2008cited by this paper
• A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.

  2007cited by this paper
• A Novel Panel of Cerebrospinal Fluid Biomarkers for the Differential Diagnosis of Alzheimer’s Disease versus Normal Aging and Frontotemporal Dementia

  2007cited by this paper
• Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders

  2006cited by this paper
• The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome.

  2006cited by this paper
• A novel approach and protocol for discovering extremely low‐abundance proteins in serum

  2006cited by this paper
• Analysis of albumin-associated peptides and proteins from ovarian cancer patients.

  2005cited by this paper
• Differential exoprotease activities confer tumor-specific serum peptidome patterns.

  2005cited by this paper
• Application of 2‐D free‐flow electrophoresis/RP‐HPLC for proteomic analysis of human plasma depleted of multi high‐abundance proteins

  2005cited by this paper
• High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures.

  2005cited by this paper
• Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples

  2005cited by this paper
• Methods in enzymology: O-glycosylation of proteins.

  2005cited by this paper
• Immunoaffinity separation of plasma proteins by IgY microbeads: Meeting the needs of proteomic sample preparation and analysis

  2005cited by this paper
• Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry.

  2005cited by this paper
• Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold.

  2005cited by this paper
• Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease

  2005cited by this paper
• Differences among techniques for high‐abundant protein depletion

  2005cited by this paper
• Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry.

  2004cited by this paper
• Identification of post‐mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease

  2003cited by this paper
• Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins.

  2001cited by this paper
• Phosphorylation of human plasma alpha2-Heremans-Schmid glycoprotein (human fetuin) in vivo.

  2001cited by this paper
• Comparison of β-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer’s disease patients: amorphic plaques and cytoskeletal changes occur independently

  1998cited by this paper

• A new predictive factor VGF based on IHC experiments, gene pathways and molecular functional groups for tumor immune microenvironment and prognosis of adrenocortical carcinoma

  2025cites this paper
• VGF and Its Derived Peptides in Amyotrophic Lateral Sclerosis

  2025cites this paper
• Involvement of the VGF/BDNF axis in the neuropathology of Alzheimer’s disease and its potential role in diagnosis and treatment

  2024cites this paper
• New preclinical biomarkers for prion diseases in the cerebrospinal fluid proteome revealed by mass spectrometry

  2024cites this paper
• Computational peptide discovery with a genetic programming approach

  2024cites this paper
• Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

  2024cites this paper
• Exploring the Potential of Bioactive Peptides: From Natural Sources to Therapeutics

  2024cites this paper
• Computational Peptide Discovery with a Genetic Programming Approach

  2023cites this paper
• Neurobiochemical, Peptidomic, and Bioinformatic Approaches to Characterize Tauopathy Peptidome Biomarker Candidates in Experimental Mouse Model of Traumatic Brain Injury

  2023cites this paper
• Could VGF and/or its derived peptide act as biomarkers for the diagnosis of neurodegenerative diseases: A systematic review

  2022cites this paper
• Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer’s Disease Patient Cohorts

  2022cites this paper
• Neurotrophin Crosstalk in the Etiology and Treatment of Neuropsychiatric and Neurodegenerative Disease

  2022cites this paper
• Peptidomic Approaches and Observations in Neurodegenerative Diseases

  2022influential citation
• VGF: A prospective biomarker and therapeutic target for neuroendocrine and nervous system disorders.

  2022cites this paper
• Biological Significance of the Protein Changes Occurring in the Cerebrospinal Fluid of Alzheimer’s Disease Patients: Getting Clues from Proteomic Studies

  2021cites this paper
• Peptidomics: A Review of Clinical Applications and Methodologies.

  2021cites this paper
• Quantitative Peptidomics of Mouse Brain After Infection With Cyst-Forming Toxoplasma gondii

  2021cites this paper
• Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology

  2021cites this paper
• Generation and Release of Neurogranin, Vimentin, and MBP Proteolytic Peptides, Following Traumatic Brain Injury

  2021cites this paper
• A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease

  2020cites this paper
• VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice

  2020cites this paper
• VGF in cerebrospinal fluid, when combined with conventional biomarkers, enhances prediction of conversion from mild cognitive impairment to Alzheimer’s Disease

  2019cites this paper
• VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD.

  2019cites this paper
• Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease

  2019cites this paper
• Proteomic studies of cerebrospinal fluid biomarkers for Alzheimer's disease: an update

  2019cites this paper
• VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies

  2019cites this paper
• ApoE4 pathology in Alzheimer's disease from the perspective of organelle dysfunction in astrocytes

  2019cites this paper
• Levels of ADAM10 are reduced in Alzheimer’s disease CSF

  2018cites this paper
• Synaptic plasticity modulation by circulating peptides and metaplasticity: Involvement in Alzheimer's disease

  2018cites this paper
• Origins, Technological Development, and Applications of Peptidomics.

  2018cites this paper
• The Challenge to Search for New Nervous System Disease Biomarker Candidates: the Opportunity to Use the Proteogenomics Approach

  2018cites this paper
• Multiscale causal network models of Alzheimer’s disease identify VGF as a key regulator of disease

  2018cites this paper
• Inter-individual differences and common features of human urine peptidome revealed by liquid chromatography–tandem mass spectrometry

  2018cites this paper
• Effect of Reproducibility of Nano-liquid Chromatography- Mass Spectrometry on Analysis of Urinary Peptidomics

  2017cites this paper
• Expanding the cerebrospinal fluid endopeptidome

  2017cites this paper
• Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid

  2017cites this paper
• Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease: an update

  2017cites this paper
• Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease

  2016cites this paper
• The Unbiased Search of Biomarkers in Neurodegenerative Diseases.

  2016cites this paper
• Exploring Biomarkers for Alzheimer's Disease.

  2016cites this paper
• Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

  2015cites this paper
• Explorative and targeted neuroproteomics in Alzheimer's disease.

  2015cites this paper
• An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

  2015cites this paper
• VGF expression by T lymphocytes in patients with Alzheimer's disease

  2015cites this paper
• The Potential of Proteomics in Understanding Neurodegeneration.

  2015cites this paper
• Peptidomics of urine and other biofluids for cancer diagnostics.

  2014cites this paper
• Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

  2014cites this paper
• Top-down peptidomics of bodily fluids

  2014cites this paper
• VGF Changes during the Estrous Cycle: A Novel Endocrine Role for TLQP Peptides?

  2014cites this paper
• Age-related increase of VGF-expression in T lymphocytes

  2014cites this paper
• Role of proteomics in biomarker discovery: prognosis and diagnosis of neuropsychiatric disorders.

  2014cites this paper
• U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease

  2013cites this paper
• Salivary Peptidome

  2013cites this paper
• New Insight into Neurodegeneration: the Role of Proteomics

  2013cites this paper
• Computational Analysis of High‐Throughput MALDI‐TOF‐MS‐Based Peptide Profiling

  2013cites this paper
• Salivary Peptidomic Analysis -The Extension of Proteomics

  2013cites this paper
• The pros and cons of multiplexing: a guest-editor's introduction.

  2012cites this paper